1. Home
  2. KRNT vs OBX Comparison

KRNT vs OBX Comparison

Compare KRNT & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kornit Digital Ltd.

KRNT

Kornit Digital Ltd.

SELL

Current Price

$16.80

Market Cap

711.1M

Sector

Industrials

ML Signal

SELL

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

N/A

Current Price

$11.66

Market Cap

839.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRNT
OBX
Founded
2002
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
711.1M
839.5M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
KRNT
OBX
Price
$16.80
$11.66
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$25.00
★ $39.00
AVG Volume (30 Days)
357.8K
★ 612.3K
Earning Date
11-04-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.48
N/A
Revenue Next Year
$7.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.93
$11.79
52 Week High
$19.78
$39.00

Technical Indicators

Market Signals
Indicator
KRNT
OBX
Relative Strength Index (RSI) 48.05 33.11
Support Level $14.56 N/A
Resistance Level $16.80 $18.21
Average True Range (ATR) 0.75 1.24
MACD -0.04 0.09
Stochastic Oscillator 29.37 5.94

Price Performance

Historical Comparison
KRNT
OBX

About KRNT Kornit Digital Ltd.

Kornit Digital Ltd is a developer and provider of digital solutions for the printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value-added services that enable large-scale printing of short-run complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink, and other consumables, and services, including software subscriptions. The company geographically operates in the U.S., EMEA, Asia Pacific, and other countries. It derives maximum revenue from the U.S.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: